Glybera: The story of gene therapy

Glybera (alipogene tiparvovec) made history on November 2 when the European Union approved its marketing application, making the gene therapy the first to win approval by Western regulators.

In many ways, the story of Glybera is the story of AAV and gene therapy itself.

Looking ahead, is the next step approval by FDA? And will they approve it? I don’t really know. I would guess uniQure is trying to partner with someone in the U.S. who may be better positioned to take this forward to FDA. It’s unclear when, or if, we’ll see an approval for Glybera in the U.S.

View the original article here: Glybera’s Story Mirrors that of Gene Therapy

Outbreak
Outbreak Daily Digest
Biotech Facts & Fallacies
Talking Biotech
Genetics Unzipped
Infographic: The evolutionary history of the COVID-19 coronavirus

Infographic: The evolutionary history of the COVID-19 coronavirus

Reuters analysed over 185,000 genome samples from the Global Initiative on Sharing All influenza Data (GISAID), the largest database of ...
favicon

Environmental Working Group: EWG challenges safety of GMOs, food pesticide residues

Known by some as the "Environmental Worrying Group," EWG lobbies ...
m hansen

Michael Hansen: Architect of Consumers Union ongoing anti-GMO campaign

Michael K. Hansen (born 1956) is thought by critics to be ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend